These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22244290)

  • 1. Oral thromboprophylaxis in pelvic trauma: a standardized protocol.
    Godoy Monzon D; Iserson KV; Cid A; Vazquez JA
    J Emerg Med; 2012 Oct; 43(4):612-7. PubMed ID: 22244290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
    Beyer-Westendorf J; Lützner J; Donath L; Tittl L; Knoth H; Radke OC; Kuhlisch E; Stange T; Hartmann A; Günther KP; Weiss N; Werth S
    Thromb Haemost; 2013 Jan; 109(1):154-63. PubMed ID: 23197272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty.
    Jameson SS; Rymaszewska M; Hui AC; James P; Serrano-Pedraza I; Muller SD
    J Bone Joint Surg Am; 2012 Sep; 94(17):1554-8. PubMed ID: 22832942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
    Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
    Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
    Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
    N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin for Thromboprophylaxis in Nonoperative Pelvic Fractures.
    Hamidi M; Zeeshan M; Sakran JV; Kulvatunyou N; O'Keeffe T; Northcutt A; Zakaria ER; Tang A; Joseph B
    J Am Coll Surg; 2019 Jan; 228(1):89-97. PubMed ID: 30359834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
    Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
    Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fatal risk thrombosis? A prospective study for the incidence of deep vein thrombosis in pelvic fractures].
    Böhme J; Müller J; Fröhlich S; Tiemann AH; Josten C
    Z Orthop Unfall; 2009; 147(3):293-7. PubMed ID: 19551579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboprophylaxis in pelvic and acetabular trauma surgery. The role of early treatment with low-molecular-weight heparin.
    Steele N; Dodenhoff RM; Ward AJ; Morse MH
    J Bone Joint Surg Br; 2005 Feb; 87(2):209-12. PubMed ID: 15736745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
    Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
    N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
    Fisher WD; Eriksson BI; Bauer KA; Borris L; Dahl OE; Gent M; Haas S; Homering M; Huisman MV; Kakkar AK; Kälebo P; Kwong LM; Misselwitz F; Turpie AG
    Thromb Haemost; 2007 Jun; 97(6):931-7. PubMed ID: 17549294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol.
    Cohen AT; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Mebazaa A; Merli G; Schellong S; Spyropoulos A; Tapson V
    J Thromb Thrombolysis; 2011 May; 31(4):407-16. PubMed ID: 21359646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-analysis model for anticoagulant treatment in the hospital setting.
    Mody SH; Huynh L; Zhuo DY; Tran KN; Lefebvre P; Bookhart B
    J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple lower-extremity and pelvic fractures increase pulmonary embolus risk.
    Godzik J; McAndrew CM; Morshed S; Kandemir U; Kelly MP
    Orthopedics; 2014 Jun; 37(6):e517-24. PubMed ID: 24972431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
    Parry TJ; Huang Z; Chen C; Connelly MA; Perzborn E; Andrade-Gordon P; Damiano BP
    Blood Coagul Fibrinolysis; 2011 Dec; 22(8):720-6. PubMed ID: 21986468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement].
    Zhang H; Lin J; Li H; Guan Z; Zhou D; Kou B; Wei W
    Zhonghua Yi Xue Za Zhi; 2014 Feb; 94(7):525-8. PubMed ID: 24767296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential duplex ultrasound screening for proximal deep venous thrombosis in asymptomatic patients with acetabular and pelvic fractures treated operatively.
    Moed BR; Miller JR; Tabaie SA
    J Trauma Acute Care Surg; 2012 Feb; 72(2):443-7. PubMed ID: 22327985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of pelvic and lower extremity fractures on the incidence of lower extremity deep vein thrombosis in high-risk trauma patients. Winner of the Best Paper Award from the Gold Medal Forum.
    Britt SL; Barker DE; Maxwell RA; Ciraulo DL; Richart CM; Burns RP
    Am Surg; 2003 Jun; 69(6):459-63; discussion 464. PubMed ID: 12852501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of rivaroxaban versus low-molecular-weight heparin therapy in patients with lower limb fractures.
    Long A; Zhang L; Zhang Y; Jiang B; Mao Z; Li H; Zhang S; Xie Z; Tang P
    J Thromb Thrombolysis; 2014 Oct; 38(3):299-305. PubMed ID: 24402194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment.
    Turpie AG; Haas S; Kreutz R; Mantovani LG; Pattanayak CW; Holberg G; Jamal W; Schmidt A; van Eickels M; Lassen MR
    Thromb Haemost; 2014 Jan; 111(1):94-102. PubMed ID: 24154549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.